Credence Research, the leading business intelligence provider, has published its latest research, “Antibody Drug Conjugate Market 2026”, which gives insights into Antibody Drug Conjugate in the Global market. The report determines the market size for 2018, along with forecasts until 2026. It is built using data and information sourced from exclusive databases, primary and secondary research, and in-house analysis carried out by Credence Research’s team of industry experts.[Continue reading..]

Market Insight: Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue.

This research report gives worldwide Antibody Drug Conjugate volume forecast and recent quarter review of major Antibody Drug Conjugate vendor performance. The report includes major vendors’ volume, growth trends, revenue and revenue growth trends, operating profit margin and ASP, along with analyst insights.

Depth Information of This report:

Key research study highlights comprise:

  1. Exhaustive research and analysis of the global Antibody Drug Conjugate industry
  2. The key market segments along have been explained in the report thoroughly along with their existing and estimated market size
  3. Major elements of market dynamics such as drivers, challenges and opportunities and their effect on Antibody Drug Conjugate market is also covered in the report
  4. Key players operating in the market are profiled and accompanied with the competitive landscape evaluated on the basis of product offering& business strength
  5. Cross sectional analysis of each region covering individual segments for the forecast period 2016 – 2018 in terms of value (US$ Mn)

Research methodology applied for this study:

Methodology of this research study includes primary and secondary research for defining the market size, shares and forecast for global Antibody Drug Conjugate market specific to key segments, and regional segmentation.

  1. Secondary Research

Secondary research was initiated with data collected through sources such as press releases, company annual reports, and relevant documents focusing on the current developments in the global Antibody Drug Conjugate market. Authentic sources such as university research papers, scientific journals, and government websites were similarly screened for identifying business opportunities in several geographical markets and penetration of various products/services in these geographies. Paid databases were excavated to assemble information beneficial for broad commercial study of the key players operating in Antibody Drug Conjugate market. In case lack of data availability on the public domain, we used estimation models to arrive at comprehensive data sets. Secondary research helped to create a firm base to build market size, analyze trends, and understand the dynamics of Antibody Drug Conjugate market study.

  1. Primary Research

The exhaustive secondary research practiced was supported & validated by extensive primary research. Primary research was carried out with the help ofe-mail interactions, telephonic interviews, as well as face-to-face interviews with the leading industry stakeholders.

The participants tracked for primary interviews include:

  • Marketing/product managers
  • Vice President/ CEOs
  • National sales managers
  • Market intelligence managers
  • Distributors
  • Purchasing managers
  • Other stakeholders


  • The report presents the brief overview of Antibody Drug Conjugate Market including business description, key information and facts, and its locations and subsidiaries
  • The report features product description and descriptive mechanism of action for key products along with the products developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued projects
  • Latest company statement
  • Latest news and deals relating to the Antibody Drug Conjugate products

Do inquiry before purchasing the research @

Table of content:

  1. Executive Summary
    2.1. Global Antibody Drug Conjugate Market Snapshot
    2.2. Global Antibody Drug Conjugate Market, by Geography, 2015 (Value %)
  2. Global Antibody Drug Conjugate Market Analysis 
    3.1. Global Antibody Drug Conjugate Market Overview
    3.2. Market Dynamics
    3.2.1. Market Drivers
    3.2.2. Challenges
    3.2.3. Opportunities
    3.3. Attractive Investment Proposition, 2015
    3.4. Competitive Landscape Assessment, By Key Market Players
  3. Global Antibody Drug Conjugate Market, By Drug, 2014 – 2024 (USD)
    4.1. Overview
    4.2. Kadcyla
    4.3. Adcetris
    4.4. Pipeline Analysis of Antibody Drug Conjugate Market, 2014 – 2024 (USD)
  4. Global Asthma Therapeutics Market, By Geography, 2014 – 2024 (USD)
    5.1. Overview
    5.2. North America
    5.2.1. U.S.
    5.2.2. Canada
    5.3. Europe
    5.3.1. U.K.
    5.3.2. Germany
    5.3.3. Rest of Europe
    5.4. Asia Pacific
    5.4.1. China …
  5. Company Profiles
    6.1. Seattle Genetics, Inc.
    6.1.1. Business Description
    6.1.2. Financial Health and Budget Allocation
    6.1.3. Product Positions/Portfolio
    6.1.4. News Coverage
    6.2. F. Hoffman-La Roche
    6.3. ImmunoGen, Inc.
    6.4. Bayer AG
    6.5. Novartis AG
    6.6. Takeda Pharmaceutical Company Limited
    6.7. Immunomedics, Inc.
    6.8. Agensys, Inc.
    6.9. Concortis Biotherapeutics
    6.10. NBE-Therapeutics …

Reasons to Buy

  • The report provides information about technology solutions needed for the implementation of Antibody Drug Conjugate projects, and allows readers to make effective business decisions
  • The report helps readers to strengthen strategic framework by understanding the business benefits to be achieved through Antibody Drug Conjugate solutions
  • The report highlights projected investment on Antibody Drug Conjugate over the next two years. This will help organizations to allocate budget towards Antibody Drug Conjugate implementation and business expansion
  • The report helps executives plan their adoption of Antibody Drug Conjugate by providing expected timeframes for implementation

Click Here for TOC and Full report:

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE, CA 95103, US